-
公开(公告)号:US20100184754A1
公开(公告)日:2010-07-22
申请号:US12651612
申请日:2010-01-04
申请人: Paul A. Renhowe , Sabina Pecchi , Timothy D. Machajewski , Cynthia M. Shafer , Clarke Taylor , William R. McCrea, JR. , Christopher McBride , Elisa Jazan
发明人: Paul A. Renhowe , Sabina Pecchi , Timothy D. Machajewski , Cynthia M. Shafer , Clarke Taylor , William R. McCrea, JR. , Christopher McBride , Elisa Jazan
IPC分类号: A61K31/541 , A61K31/4709 , A61K31/497 , A61K31/5377 , A61P35/04
CPC分类号: C07D471/04 , A61K31/19 , A61K31/439 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/5377 , A61K31/541 , C07D401/04 , C07D401/14 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D453/02 , A61K2300/00
摘要: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
摘要翻译: 提供具有式I和II的有机化合物,其中变量具有本文所述的值。 药物制剂包括有机化合物或其药学上可接受的盐和药学上可接受的载体,并且可以通过将有机化合物的有机化合物或药学上可接受的盐与载体和水混合来制备。 治疗患者的方法包括向有需要的患者施用本发明的药物制剂。
-
公开(公告)号:US06800760B2
公开(公告)日:2004-10-05
申请号:US10613411
申请日:2003-07-03
申请人: Paul A. Renhowe , Sabina Pecchi , Timothy D. Machajewski , Cynthia M. Shafer , Clarke Taylor , William R. McCrea, Jr. , Christopher McBride , Elisa Jazan
发明人: Paul A. Renhowe , Sabina Pecchi , Timothy D. Machajewski , Cynthia M. Shafer , Clarke Taylor , William R. McCrea, Jr. , Christopher McBride , Elisa Jazan
IPC分类号: C07D21516
CPC分类号: C07D409/04 , A61K31/19 , A61K31/4709 , A61K31/4745 , A61K31/513 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/04 , C07D417/04 , C07D453/02 , C07D471/04 , A61K2300/00
摘要: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
-
23.
公开(公告)号:US07326711B2
公开(公告)日:2008-02-05
申请号:US10870707
申请日:2004-06-17
申请人: Weibo Wang , Ryan N. Constantine , Liana Marie Lagniton , Sabina Pecchi , Matthew T. Burger , Manoj C. Desai
发明人: Weibo Wang , Ryan N. Constantine , Liana Marie Lagniton , Sabina Pecchi , Matthew T. Burger , Manoj C. Desai
IPC分类号: A61K31/519 , A61K35/00 , C07D487/04
CPC分类号: C07D471/04
摘要: Pyridin[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译: 吡啶并[1,2-a]嘧啶基化合物,其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种吡啶并[1,2-a]嘧啶基化合物的组合物,单独或与至少一种另外的治疗剂组合。 单独或与至少一种其它治疗剂组合使用吡啶并[1,2-a]嘧啶基化合物在预防或治疗增殖性疾病中的方法。
-
公开(公告)号:US20070032528A1
公开(公告)日:2007-02-08
申请号:US11546814
申请日:2006-10-11
IPC分类号: A61K31/4439 , C07D417/04 , C07D413/04 , C07D403/04
CPC分类号: C07D471/04 , C07D495/04
摘要: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
摘要翻译: 提供具有结构式I的有机化合物,其中变量具有本文所述的值,并且R 1和R 2连接在一起以形成6元取代或未取代的环,其包括在 至少一个O,N或S原子,Z是O,S,NH或NR基团。 药物制剂包括有机化合物或其药学上可接受的盐和药学上可接受的载体。
-
公开(公告)号:US20050137188A1
公开(公告)日:2005-06-23
申请号:US10823995
申请日:2004-04-14
IPC分类号: A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61P9/00 , A61P35/00 , A61P43/00 , C07D471/04 , C07D495/04 , C07D519/00 , A61K31/551 , A61K31/4439 , A61K31/4545 , A61K31/541 , C07D413/14 , C07D417/14
CPC分类号: C07D471/04 , C07D495/04
摘要: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
摘要翻译: 提供具有结构式I的有机化合物,其中变量具有本文所述的值,并且R 1和R 2连接在一起以形成6元取代或未取代的环,其包括在 至少一个O,N或S原子,Z是O,S,NH或NR基团。 药物制剂包括有机化合物或其药学上可接受的盐和药学上可接受的载体。
-
公开(公告)号:US20050209456A1
公开(公告)日:2005-09-22
申请号:US11092137
申请日:2005-03-29
IPC分类号: C07D243/08 , A61K31/19 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/5377 , A61K31/541 , A61K31/551 , A61P35/00 , A61P43/00 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D417/04 , C07D453/02 , C07D471/04 , C07D487/08 , C07D519/00 , C07D43/02
CPC分类号: C07D409/04 , A61K31/19 , A61K31/4709 , A61K31/4745 , A61K31/513 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/04 , C07D417/04 , C07D453/02 , C07D471/04 , A61K2300/00
摘要: A method for synthesizing a 4-amino substituted quinolinone includes reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a substituted or unsubstituted 2-aminobenzonitrile in the presence of a base or an acid. A 4-amino substituted quinolinone compound is formed by the reaction, and the 4-amino substituted quinolinone compound comprises a benzimidazole group.
摘要翻译: 合成4-氨基取代的喹啉酮的方法包括在碱或酸的存在下使取代或未取代的2-苯并咪唑-2-乙酸酯与取代或未取代的2-氨基苄腈反应。 通过反应形成4-氨基取代的喹啉酮化合物,4-氨基取代的喹啉酮化合物包括苯并咪唑基。
-
公开(公告)号:US20100075965A1
公开(公告)日:2010-03-25
申请号:US12279148
申请日:2007-02-14
申请人: Zhi-Jie Ni , Sabina Pecchi , Matthew Burger , Wooseok Han , Aaron Smith , Gordana Atallah , Sarah Bartulis , Kelly Frazier , Joelle Verhagen , Yanchen Zhang , Ed Iwanowicz , Tom Hendrickson , Mark Knapp , Hanne Merritt , Charles Voliva , Marion Wiesmann , Darren Mark Legrand , Ian Bruce , James Dale , Jiong Lan , Barry Levine , Abran Costales , Jui Liu , Teresa Pick , Daniel Menezes
发明人: Zhi-Jie Ni , Sabina Pecchi , Matthew Burger , Wooseok Han , Aaron Smith , Gordana Atallah , Sarah Bartulis , Kelly Frazier , Joelle Verhagen , Yanchen Zhang , Ed Iwanowicz , Tom Hendrickson , Mark Knapp , Hanne Merritt , Charles Voliva , Marion Wiesmann , Darren Mark Legrand , Ian Bruce , James Dale , Jiong Lan , Barry Levine , Abran Costales , Jui Liu , Teresa Pick , Daniel Menezes
IPC分类号: A61K31/5377 , C07D471/04 , C07D487/04 , C07D413/14 , A61K31/437 , A61K31/5025 , A61P35/00
CPC分类号: C07D487/04 , C07D417/04 , C07D417/14 , C07D471/04
摘要: Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.
摘要翻译: 磷脂酰肌醇(PI)3激酶抑制剂化合物,其药学上可接受的盐和前药; 单独或与至少一种另外的治疗剂组合的新化合物与药学上可接受的载体的组合物; 以及单独或与至少一种另外的治疗剂联合使用的新化合物在预防或治疗以生长因子,蛋白丝氨酸/苏氨酸激酶,磷脂激酶,G蛋白偶联的异常活性为特征的增殖性疾病中的用途 受体和磷酸酶。
-
公开(公告)号:US08563553B2
公开(公告)日:2013-10-22
申请号:US13473230
申请日:2012-05-16
申请人: Abran Q. Costales , Shenlin Huang , Jeff Xianming Jin , Zuosheng Liu , Sabina Pecchi , Daniel Poon , John Tellew
发明人: Abran Q. Costales , Shenlin Huang , Jeff Xianming Jin , Zuosheng Liu , Sabina Pecchi , Daniel Poon , John Tellew
IPC分类号: A61K31/50
CPC分类号: C07D403/04 , A61K31/506 , A61K45/06
摘要: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
摘要翻译: 本发明提供式I或II的化合物:其中R1,R1b,R2,R3,R4,R5,R6和R7如本文所定义。 式(I)或(II)的化合物及其药物组合物可用于治疗B-Raf相关疾病。
-
公开(公告)号:US08173647B2
公开(公告)日:2012-05-08
申请号:US12449286
申请日:2008-02-06
申请人: Gordana Atallah , Sarah Bartulis , Matthew Burger , Hanne Merritt , Simon Ng , Zhi-Jie Ni , Sabina Pecchi , Keith B. Pfister , Aaron Smith , Charles Voliva , Allan Wagman , Yanchen Zhang
发明人: Gordana Atallah , Sarah Bartulis , Matthew Burger , Hanne Merritt , Simon Ng , Zhi-Jie Ni , Sabina Pecchi , Keith B. Pfister , Aaron Smith , Charles Voliva , Allan Wagman , Yanchen Zhang
IPC分类号: A61K31/5377 , C07D413/14
CPC分类号: C07D401/14 , C07D401/04 , C07D405/14 , C07D413/14
摘要: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases.
摘要翻译: 磷脂酰肌醇(PI)3-激酶抑制剂化合物,其药学上可接受的盐和前药; 单独或与至少一种另外的治疗剂组合的新化合物与药学上可接受的载体的组合物; 以及单独或与至少一种另外的治疗剂组合的新化合物在预防或治疗特征在于生长因子异常活性,蛋白质丝氨酸/苏氨酸激酶和磷脂激酶(包括增殖性疾病)的疾病中的用途, 炎性和阻塞性气道疾病,过敏性疾病,自身免疫性疾病和心血管疾病。
-
公开(公告)号:US07335774B2
公开(公告)日:2008-02-26
申请号:US11092137
申请日:2005-03-29
申请人: Paul A. Renhowe , Cynthia M. Shafer , Timothy D. Machajewski , Sabina Pecchi , Christopher McBride
发明人: Paul A. Renhowe , Cynthia M. Shafer , Timothy D. Machajewski , Sabina Pecchi , Christopher McBride
IPC分类号: C07D215/38
CPC分类号: C07D409/04 , A61K31/19 , A61K31/4709 , A61K31/4745 , A61K31/513 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/04 , C07D417/04 , C07D453/02 , C07D471/04 , A61K2300/00
摘要: A method for synthesizing a 4-amino substituted quinolinone includes reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a substituted or unsubstituted 2-aminobenzonitrile in the presence of a base or an acid. A 4-amino substituted quinolinone compound is formed by the reaction, and the 4-amino substituted quinolinone compound comprises a benzimidazole group.
摘要翻译: 合成4-氨基取代的喹啉酮的方法包括在碱或酸的存在下使取代或未取代的2-苯并咪唑-2-乙酸酯与取代或未取代的2-氨基苄腈反应。 通过反应形成4-氨基取代的喹啉酮化合物,4-氨基取代的喹啉酮化合物包括苯并咪唑基。
-
-
-
-
-
-
-
-
-